|
MASTER-01
|
Breast cancer metastasis
|
104
|
3410
|
BRCA1/2 deletions
|
PARP inhibitors
|
43
|
Yes
|
B2
|
11.6%
|
|
RAF1, PDGFRA amplifications
|
Sorafenib
| |
Yes
|
B3
|
4.6%
|
|
FGF1 (T8N)
|
FGFR inhibitor
| |
Yes
|
–
|
2.3%
|
|
MASTER-02
|
Pancreatic adenocarcinoma
|
49
|
1528
|
KRAS (G12D)
|
–
|
92
|
–
|
–
|
–
|
|
MASTER-03
|
Leiomyosarcoma of the retroperitoneum
|
31
|
3181
|
PTPRJ deletion
|
Pazopanib
|
12
|
No
|
–
|
–
|
|
CDK12 + BRCA2 deletions
|
Cisplatin
| |
Yes
|
B2
|
50%
|
|
MASTER-04
|
Ovarian carcinoma
|
98
|
3385
|
TSC2 (R505X)
|
mTOR inhibitor
|
56
|
Yes
|
B2
|
12.5%
|
|
MASTER-05
|
Myxoid liposarcoma
|
11
|
72
|
PIK3CA (C420R) + PTEN (R130G)
|
mTOR inhibitor
|
75
|
Yes
|
B2
|
9.3%
|
| |
AKT inhibitor
| |
Yes
|
B2
|
2.4%
|
| |
PI3K inhibitor
| |
Yes
|
B2
|
32%
|
|
MASTER-06
|
Neuroendocrine tumor
|
2703
|
2060
|
MTOR (P2490L, G332R)
|
mTOR inhibitor
|
89
|
Yes
|
B2
|
16.8%
|
|
PTPN12 (S509 N, G523S)
|
Lapatinib, erlotinib, imatinib, desatinib
| |
No
|
–
|
–
|
|
KIT (A837T)
|
Imatinib, desatinib
| |
Yes
|
B3
|
1.1%
|
|
LCK (P74L)
|
Desatinib
| |
No
|
–
|
–
|
|
MASTER-07
|
Neuroendocrine tumor
|
645
|
941
|
ERBB3 (V104 M), RAF1 (S259P), MTOR (E1485G)
|
mTOR inhibitor
|
40
|
Yes
|
A2
|
12.5%
|
|
MASTER-08
|
Cholangiocarcinoma
|
28
|
1001
|
ERRFI1 (R199X)
|
Erlotinib
|
17
|
Yes
|
–
|
0.58%
|
|
MASTER-09
|
Clear cell sarcoma
|
11
|
1
|
NTRK3 (R116W)
|
Lestaurtinib, midostaurin
|
3
|
No
|
–
|
–
|
|
MASTER-10
|
Histiocytic sarcoma
|
7
|
5
|
BRAF (F595 L) + HRAS (Q61R)
|
MEK inhibitor
|
11
|
Yes
|
B2
|
33.3%
|
|
sorafenib (multi TKi)
| |
Yes
|
B3
|
5.5%
|
|
MASTER-11
|
Pulmonary adenocarcinoma
|
70
|
146
|
EGFR (p.745-750del)
|
Erlotinib
|
54
|
Yes
|
B2
|
22.2%
|
